Kira Pharma to Start Phase II Trials of Biologic Targeting Two Complement Pathways for Severe Lupus

Kira Pharma was cleared to start Phase II trials of its lead candidate, a first-in-class bifunctional biologic that targets the alternative and terminal complement pathways to treat lupus. The Phase II trial will evaluate the efficacy, safety and other key factors of KP104 in participants with systemic lupus erythematosus associated thrombotic microangiopathy in the US, China and Australia. In its Phase I trial, KP104 demonstrated proof-of-mechanism for both the terminal and alternative complement pathways. A Phase II trial in SLE-TMA also delivered encouraging data. Headquartered in Cambridge, MA, Kira also has facilities in China and Australia. More details....

Share this with colleagues: